Quest Diagnostics Inc banner

Quest Diagnostics Inc
NYSE:DGX

Watchlist Manager
Quest Diagnostics Inc Logo
Quest Diagnostics Inc
NYSE:DGX
Watchlist
Price: 191.51 USD -3.19% Market Closed
Market Cap: $21B

Quest Diagnostics Inc
Narrow Economic Moat

No Moat
Narrow
Wide
What is Economic Moat?

Narrow moat driven primarily by proprietary data and scale-based advantages, reinforced by entrenched payer and hospital relationships that raise rivals’ barriers to entry.

Quest Diagnostics Inc
Competitive Advantages

High Switching Costs

Extensive in‑network payer contracts and embedded hospital partnerships/CoLab solutions create operational and contractual frictions that make it costly for customers and health systems to move testing volume to competitors. ([pestel-analysis.com](https://pestel-analysis.com/products/questdiagnostics-marketing-mix?utm_source=openai))

Intangible Assets

Largest proprietary de-identified clinical-data repository and broad test menu that Quest monetizes for analytics and advanced diagnostics, creating unique, hard-to-replicate diagnostic intelligence. ([ebusiness.com](https://ebusiness.com/report/questdiagnostics.com?utm_source=openai))

Efficient Scale

Nationwide, centralized laboratory network plus automation and process programs (e.g., INFIGURATE/automation initiatives) deliver scale economies in throughput, turnaround time, and cost per test. ([fool.com](https://www.fool.com/earnings/call-transcripts/2026/02/10/quest-diagnostics-dgx-earnings-call-transcript/?utm_source=openai))

View Wide Economic Moat Stocks

Wide Economic Moat Companies

Company Last Price Price Change Market Cap Economic Moat
NVIDIA Corp
NVDA
$188.63
+0.9%
$4.6T Wide
Apple Inc
AAPL
$260.48
+2.1%
$3.8T Wide
Alphabet Inc
GOOGL
$317.24
-0.2%
$3.8T Wide
Microsoft Corp
MSFT
$370.87
+1%
$2.8T Wide
Amazon.com Inc
AMZN
$238.38
+1.8%
$2.6T Wide
Taiwan Semiconductor Manufacturing Co Ltd
2330
NT$1 990
+2.6%
$1.6T Wide
Meta Platforms Inc
META
$629.86
+0.1%
$1.6T Wide
Broadcom Inc
AVGO
$371.55
-2.1%
$1.8T Wide
Walmart Inc
WMT
$126.77
+0.6%
$1T Wide
Eli Lilly and Co
LLY
$939.47
-1.3%
$888.2B Wide
Load More
Company Last Price Price Change Market Cap Economic Moat
AstraZeneca PLC
AZN
GBX15 230
-0.1%
$318.7B Wide
Kweichow Moutai Co Ltd
600519
¥1 455.39
+1.7%
$264.8B Wide
Novo Nordisk A/S
NOVO B
kr241
-1.9%
$168.8B Wide
Zhongji Innolight Co Ltd
300308
¥739.14
+2.6%
$119.3B Wide
Advantest Corp
6857
¥24 990
+7.3%
$118.3B Wide
Eoptolink Technology Inc Ltd
300502
¥519.7
+2.7%
$75B Wide
Disco Corp
6146
¥66 890
+5.3%
$46.9B Wide
Gold Fields Ltd
GFI
Zac80 076
-1.5%
$44.9B Wide
Suzhou TFC Optical Communication Co Ltd
300394
¥361.96
-4.1%
$40.9B Wide
GE Healthcare Technologies Inc
GEHC
$73.18
+0%
$33.4B Wide
Load More

Quest Diagnostics Inc
Glance View

In the rapidly evolving world of healthcare, Quest Diagnostics Inc. stands as a pivotal player, shaping the future of diagnostic services. Born out of a quest for innovation in clinical testing, Quest Diagnostics operates at the intersection of medical science and cutting-edge technology. The company has a wide-reaching network of laboratories and service centers, offering a comprehensive array of diagnostic testing solutions that range from routine blood tests to advanced genetic screening. Their services are not limited to hospitals and physician offices; they extend into a variety of sectors including pharmaceuticals, food, and global business services, completing over a hundred million clinical laboratory tests annually. Quest's robust infrastructure and commitment to precision ensure that patients and healthcare providers receive timely and accurate information that is crucial for early detection, diagnosis, and informed treatment decisions. Quest Diagnostics' revenue model is straightforward yet effective, driven primarily by service fees from its expansive menu of tests. By collaborating with insurers, healthcare providers, and employers, Quest ensures broad access to its services. Moreover, the company continually invests in research and development to expand its test portfolio and enhance the quality of its services, thus staying competitive in the fast-paced healthcare environment. Through strategic acquisitions and partnerships, Quest has broadened its geographical reach and bolstered its technological capabilities, maintaining its position as an industry leader. As healthcare increasingly leans toward personalized medicine and preventive care, Quest Diagnostics is poised to leverage its analytical prowess and deep repository of health data to drive future growth and innovation, serving as an indispensable ally in global public health.

DGX Intrinsic Value
184.94 USD
Overvaluation 3%
Intrinsic Value
Price $191.51
The Power of Economic Moat

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

The Power of
Economic Moat
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett